Case 36Pivotal Validation And ScaleFailure

CureVac CVnCoV pivotal validation and first-generation scale

CureVac N.V. · 2020–2021

At a conservative constructed public-information boundary before the contemplated year-end pivotal start, how should CureVac sequence first-generation CVnCoV validation and irreversible manufacturing and commercial scale commitments?

Start with Part A Read outcome & teaching note

At the decision boundary

CureVac CVnCoV pivotal validation and scale decision

Decision time: December 10, 2020
Knowledge cutoff: December 10, 2020
Recommended path: Run the decisive experiment while preserving the option to expand, redirect, or stop before every first-generation manufacturing and commercial commitment becomes irreversible.
Confidence: Moderate

What happened

CureVac proceeded with HERALD and first-generation manufacturing and commercial preparations, then withdrew CVnCoV from the EMA process, ended the acute-use advance-purchase path, and shifted focus to second-generation candidates.

Proceeding to a decisive pivotal test was reasonable on the cutoff evidence, but the later scale costs support tighter staging of irreversible first-generation commitments; favorable final statistical significance does not retroactively make the regulatory and commercial process successful.

Case inventory

What is inside

14source records

9financial tables

25material claims

2candidate rules

Transfer with care

Rule hypotheses from this case

All rule hypotheses →

Candidatemoderate confidence

rule.curevac.stage-scale-behind-pivotal-gates

Run the decisive validation while staging later irreversible scale behind predeclared evidence and timing gates.

Staging preserves information and upside while reducing stranded-capacity and termination exposure if the product is statistically modest, delayed, or not regulatorily acceptable.

Candidatemoderate confidence

rule.curevac.separate-conditional-support-from-sales

Model each cash receipt, contract liability, accounting release, option, and delivered-dose sale as a separate state-contingent item.

Separating cash timing and accounting classification prevents conditional support from masquerading as recurring product demand or unit economics.

Read against

A contrasting case sharpens the boundary.

Pivotal Validation And ScaleModerna mRNA-1273 pivotal validation and at-risk scaleAt an instructor-defined public Phase 3 launch boundary on July 27—not a claim about an internal board-decision time—and using only evidence public through the end of July 26 Eastern time before first-dose execution, should Moderna proceed with pivotal validation and at-risk manufacturing, and under what clinical, funding and release gates?